Update shared on12 Sep 2025
Fair value Increased 2.41%The slight upward revisions in both Raia Drogasil’s expected revenue growth and future P/E reflect improved growth prospects, leading analysts to raise their consensus price target from R$21.54 to R$22.06.
What's in the News
- Board approved payment of BRL 131.8 million in interest on equity, equivalent to BRL 0.076940867 per share, to be paid by December 5, 2025; no monetary restatement applies.
Valuation Changes
Summary of Valuation Changes for Raia Drogasil
- The Consensus Analyst Price Target has risen slightly from R$21.54 to R$22.06.
- The Future P/E for Raia Drogasil has risen slightly from 30.23x to 30.96x.
- The Consensus Revenue Growth forecasts for Raia Drogasil has risen slightly from 13.9% per annum to 14.2% per annum.
Disclaimer
AnalystConsensusTarget is a tool utilizing a Large Language Model (LLM) that ingests data on consensus price targets, forecasted revenue and earnings figures, as well as the transcripts of earnings calls to produce qualitative analysis. The narratives produced by AnalystConsensusTarget are general in nature and are based solely on analyst data and publicly-available material published by the respective companies. These scenarios are not indicative of the company's future performance and are exploratory in nature. Simply Wall St has no position in the company(s) mentioned. Simply Wall St may provide the securities issuer or related entities with website advertising services for a fee, on an arm's length basis. These relationships have no impact on the way we conduct our business, the content we host, or how our content is served to users. The price targets and estimates used are consensus data, and do not constitute a recommendation to buy or sell any stock, and they do not take account of your objectives, or your financial situation. Note that AnalystConsensusTarget's analysis may not factor in the latest price-sensitive company announcements or qualitative material.